Which HP Phenotype is More Common: Inflammatory or Fibrotic?
The available evidence does not definitively establish which phenotype of hypersensitivity pneumonitis is more common, as the major guidelines focus on classification and diagnosis rather than epidemiological prevalence data. However, the clinical literature and diagnostic frameworks suggest that presentation patterns vary significantly based on exposure characteristics, geographic factors, and the timing of diagnosis 1, 2.
Key Points About HP Phenotype Distribution
Classification Framework
- Current guidelines classify HP into nonfibrotic (inflammatory) and fibrotic phenotypes based on the presence or absence of fibrosis on imaging or histopathology, rather than temporal categories 1, 3.
- This classification replaced the older "acute, subacute, chronic" terminology because fibrosis—not exposure duration—is the dominant determinant of prognosis and survival 3.
Clinical Presentation Patterns
Nonfibrotic (Inflammatory) HP:
- Results from intermittent, high-level antigen exposure, typically manifesting within hours to weeks 2.
- Characterized by inflammatory changes without radiographic or histopathological evidence of fibrosis 1, 3.
- More commonly associated with identifiable acute exposures (e.g., farmer's lung, bird fancier's lung with acute presentation) 1.
Fibrotic HP:
- Typically originates from long-term, low-level exposure (usually to birds or molds in the home), occurring over weeks, months, or years 2.
- Defined by extensive reticulation, traction bronchiectasis, and/or honeycombing on HRCT 3.
- Associated with significantly worse prognosis, with a 4.35-fold higher risk of death compared to nonfibrotic HP 3.
Geographic and Exposure Variability
- The prevalence and incidence of HP vary widely depending on intensity of exposure, geographical area, and local climate 2.
- Environmental, cultural, and occupational factors significantly influence which phenotype presents more commonly in different populations 4.
Prognostic Implications
Why This Distinction Matters Clinically
Nonfibrotic HP outcomes:
- Complete antigen avoidance results in no recurrence or development of fibrosis in patients who achieve it 5.
- In one cohort, 54.5% of patients with incomplete antigen avoidance experienced recurrence and/or development of fibrosis 5.
- Prognosis is favorable with potential for complete recovery when antigen is avoided 3.
Fibrotic HP outcomes:
- All-cause 5-year mortality rate of 47.8% in patients with fibrotic HP 5.
- Each unit increase in quantitative fibrosis score on HRCT raises mortality hazard by 1.54 3.
- Presence of pulmonary fibrosis on CT independently increases mortality risk 2.43-fold after adjustment for age and lung function 3.
Clinical Caveat
The apparent "commonness" of either phenotype depends heavily on when patients present for diagnosis. Patients with acute, high-level exposures may present earlier with inflammatory disease, while those with insidious, low-level exposures may not seek medical attention until fibrosis has developed 2. This creates a diagnostic bias where the phenotype distribution in clinical practice may not reflect true population-level incidence 4.